Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Cash equivalents $ 0 $ 0 $ 0 $ 0
Revenue     0 0
Research and Development Expense 164,378 96,943 $ 385,785 206,943
Income tax likely hood percentage, description     A valuation allowance is applied when in management’s view it is more likely than not (50%) that such deferred tax will not be utilized.  
Cash FDIC insured amount 808,800   $ 808,800  
Revenue
Research and Development Expense [Member]        
Research and development expenses costs incurred $ 164,378 $ 385,785 $ 164,378 $ 385,785